The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
Official Title: An Open-Label, Multinational, Multicenter, Phase IIIB Study to Assess Safety of Rituximab Following Subcutaneous Administration in Patients With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A
Study ID: NCT02406092
Brief Summary: This open-label, single-arm study will evaluate the safety of rituximab subcutaneously (SC) administered during first line treatment for follicular non-Hodgkin's lymphoma (NHL) (Induction and/or Maintenance treatment plus 24 months of follow up), or diffuse large B-cell lymphoma (DLBCL) (treatment plus 24 months of follow-up).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Hôpital Dorban CHU Annaba, Service d'Hématologie, Annaba, , Algeria
EHS CAC Hospital FRANTZ FANON ZABANA BLIDA; Hematology ward, Blida, , Algeria
EHU Oran, Service d'Hématologie et de Thérapie Cellulaire, Oran, , Algeria
Centre hospitalo-univerisitaire de Tizi Ouzou - Nedir Mohamed;Service d'hématologie, Tizi Ouzou, , Algeria
CHU 20 Aout Service D'Onco-Hematologie Pediatrique, Casablanca, , Morocco
Clinique AlMadina; Service hematologie, Casablanca, , Morocco
Centre Hospitalier Uni Ire de Marrakech; Oncologie-Hématologie, Marrakech, , Morocco
CHU Ibn Sina Rabat Service de medecine interne, Rabat, , Morocco
CHU Fattouma Bourguiba, Monastir; Service d'hématologie, Monastir, , Tunisia
CHU Hédi Chacker; Service d'hématologie, Sfax, , Tunisia
CHU Farhat Hached; Service d'hématologie, Sousse, , Tunisia
Aziza Othmana Hospital; Clinical Haematology, Tunis, , Tunisia
Hopital Militaire d'instruction de Tunis; Service d'hématologie, Tunis, , Tunisia
Name: Clinical Trials
Affiliation: Hoffmann-La Roche
Role: STUDY_DIRECTOR